

***Fiscal Year 2022 Department of Defense Tick-Borne Disease Research Program (TBDRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Idea Development Award (IDA)</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>W81XWH-22-TBDRP-IDA</p>	<p>IDA:</p> <p>Independent investigators at or above the level of Assistant Professor (or equivalent)</p> <p>IDA – Career Development Option:</p> <ul style="list-style-type: none"> Principal Investigator (PI) – Investigator within 10 years of completing their terminal degree at the time of <u>their</u> application submission and working to become an independent investigator in <u>tick-borne disease (TBD)</u> research. Mentor – Independent investigator at or above the level of Associate Professor (or equivalent); must be an experienced TBD researcher as demonstrated by a recent history of funding and publications in TBD research, specifically in the field of the proposed studies. <i>Mentorship is required. The PI and Mentor may be at different organizations.</i> 	<ul style="list-style-type: none"> Prevention and Pathogenesis Focus Areas only. Supports research that could lead to impactful discoveries or significant advancements that will accelerate progress toward reducing the burden of Lyme disease and/or other TBDs and conditions and improving patient care and/or quality of life. Research should be conceptually innovative, exhibit high levels of creativity, or challenge existing research paradigms. Applications must describe the short- and long-term impact of the proposed research, as well as the public health burden of the diseases being addressed. The Career Development Option is intended to fund early-career investigators to conduct impactful research under the mentorship of an experienced TBD researcher. Applications submitted under this option will be reviewed via separate, career development-specific evaluation criteria by a separate, dedicated peer review panel. Preliminary data are required unless submitting under the Career Development Option. Clinical trials are not allowed; human studies/clinical research are permitted. Pre-application submission is required; application submission is by invitation only. 	<p>IDA:</p> <ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$500,000 for direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. The maximum period of performance is 3 years. <p>IDA – Career Development Option:</p> <ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$300,000 for direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. The maximum period of performance is 3 years. 	<p>Pre-Application (Preproposal): May 26, 2022 5:00 p.m. Eastern Time (ET)</p> <p>Application: August 25, 2022 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Therapeutic/Diagnostic Research Award (TDRA)</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>W81XWH-22-TBDRP-TDRA</p>	<p>TDRA:</p> <p>Independent investigators at or above the level of Assistant Professor (or equivalent)</p> <p>TDRA – Career Development Option:</p> <ul style="list-style-type: none"> Principal Investigator (PI) – Investigator within 10 years of completing their terminal degree at the time of their application submission and working to become an independent investigator in TBD research. Mentor – Independent investigator at or above the level of Associate Professor (or equivalent); must be an experienced TBD researcher as demonstrated by a recent history of funding and publications in TBD research, specifically in the field of the proposed studies. <i>Mentorship is required. The PI and Mentor may be at different organizations.</i> 	<ul style="list-style-type: none"> Treatment and Diagnosis Focus Areas only. Supports hypothesis-driven therapeutic and diagnostic development research aimed at reducing the burden of Lyme disease and/or other TBDs and conditions and improving patient care and/or quality of life. <ul style="list-style-type: none"> Treatment-focused applications should be therapeutic evaluation studies designed to promote new ideas aimed at drug or treatment discovery that are still in the early/preclinical stages of development. Diagnosis-focused applications should propose diagnostic approaches that will be readily integrated into clinical settings. Research should have translational potential, with proposed studies expected to be empirical in nature and product-driven. Applicants with limited TBD experience are strongly encouraged to collaborate with experienced TBD investigators. Applicants with substantial TBD experience are strongly encouraged to partner with experts in therapeutic and diagnostic assay development and transition, particularly those from the commercial sector. The Career Development Option is intended to fund early-career investigators to conduct impactful research under the mentorship of an experienced TBD researcher. Applications submitted under this option will be reviewed via separate, career-development-specific evaluation criteria by a separate, dedicated peer review panel. Preliminary data are required unless submitting under the Career Development Option. Clinical trials are not allowed; human studies/clinical research are permitted. <i>Pre-application submission is required; application submission is by invitation only.</i> 	<p>TDRA:</p> <ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$825,000 for direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. The maximum period of performance is 3 years. <p>TDRA – Career Development Option:</p> <ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$495,000 for direct costs. Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. The maximum period of performance is 3 years. 	<p>Pre-Application (Preproposal): May 26, 2022 5:00 p.m. ET</p> <p>Application: August 25, 2022 11:59 p.m. ET</p>